With Palforzia® Ending, What’s Next for Peanut Allergy Patients?
Published: February 19, 2026 Revised: August 3rd, 2026
At a Glance: Palforzia® Ending, What’s Next
- Palforzia® discontinued. The peanut allergy oral immunotherapy (OIT) treatment was discontinued on July 31, 2026. The manufacturer, Stallergenes Greer, said the discontinuation was not related to the product’s safety, quality, or effectiveness.
- What is Palforzia? Palforzia helped desensitize the immune system to peanut. It reduced the risk of severe allergic reactions after accidental peanut exposure.
- Do not start or stop peanut allergy treatment on your own. If you are considering oral immunotherapy (OIT) or are affected by the discontinuation of Palforzia, talk with a board-certified allergist about your treatment options.
- Office-based peanut OIT. Some allergists offer office-based oral immunotherapy (OIT) using standardized protocols. These treatments are not FDA-approved, and insurance coverage may vary.
- Xolair® (omalizumab). This biologic is FDA-approved for IgE-mediated food allergy. It helps reduce the risk of allergic reactions from accidental exposure to one or more food allergens.
- Investigational treatments. Viaskin® Peanut (peanut patch) and sublingual immunotherapy (SLIT) are not FDA-approved. They continue to be studied as peanut allergy treatments.
The peanut allergy treatment Palforzia® was discontinued on July 31, 2026. Palforzia was the first and only oral immunotherapy (OIT) approved by the U.S. Food and Drug Administration (FDA). It treated peanut allergy in children ages 1 through 17.
Palforzia earned FDA approval in 2020. It was originally developed by Aimmune. Nestle Health Science bought Aimmune and then sold Palforzia to Stallergenes Greer.
The notice that Stallergenes Greer posted to the Palforzia website reads: “This voluntary discontinuation is not related to product safety, quality, or efficacy.”
Palforzia treatment involved taking a carefully measured daily dose of peanut powder. The amount gradually increased over time under the supervision of an allergist. Palforzia was not a cure for peanut allergy. Instead, it worked to desensitize the immune system, reducing the risk of a severe allergic reaction after accidental exposure to peanuts.
Allergy & Asthma Network asked board-certified allergist Purvi Parikh, MD, to comment on the loss of Palforzia as a peanut allergy treatment.
“It is disappointing to lose an oral immunotherapy option for peanut allergy,” Dr. Parikh says. “While methods such as early introduction have helped prevent peanut allergy, this was the only FDA-approved immunotherapy option for children who already had a developed peanut allergy.
“The benefit of FDA approval is increased access to treatments and insurance coverage for these treatments. I hope we see more FDA-approved immunotherapy options on the horizon for our food allergy community.”
What Are Options for Peanut Allergy Treatment?
First, do NOT attempt peanut allergy OIT on yourself or your child. OIT is a specialized treatment that should only be taken in consultation with a food allergy specialist. There is a risk of a serious allergic reaction, including life-threatening anaphylaxis.
Parents who want to continue their child on peanut allergy therapy, or OIT in general, should talk with their child’s healthcare provider. Continued daily peanut exposure is typically required to maintain desensitization.
Are there alternatives to Palforzia? Yes, but some are not FDA-approved. Their availability may vary on whether allergists offer the treatment. And insurance may not cover non-FDA-approved therapies.
Office-based treatments
Ask your allergist if an office-based OIT is available. Some allergists who specialize in food allergy treatment may offer OIT for peanut and other food allergens using an office-based product. The allergist would prepare a non-pharmaceutical grade OIT product using specific measurements and standardized protocols.
While office-based OIT is not FDA-approved, it has proven to be beneficial for many food allergy patients.
Biologic treatments
Talk with your allergist about whether taking a biologic for food allergy therapy is right for you. FDA has approved omalizumab (Xolair®) for adults and children ages 1-17 with an IgE-mediated food allergy. It reduces the risk of allergic reactions due to an accidental exposure. Xolair also reduces the risk and severity of an allergic reaction. The treatment is given as an injection every 2-4 weeks.
Sublingual immunotherapy (SLIT)
Ask your allergist about SLIT for food allergy therapy. This involves placing drops of a food allergen protein extract under the tongue for two minutes, then spitting it out or swallowing. SLIT is not FDA-approved. A 2019 study of SLIT for food allergies showed promise in children ages 1 to 11. More research is needed to prove it is safe and effective.
Viaskin® Peanut
A future food allergy treatment could be Viaskin® Peanut from DBV Technologies. The product is commonly referred to as the “peanut patch.” Viaskin Peanut is not FDA-approved but it is on a path toward approval.
The peanut patch involves attaching to the skin an adhesive patch that contains a tiny dose of peanut allergen. It works to desensitize patients to peanut and increase tolerance. It offers increased protection from an accidental exposure.
DBV Technologies is working with FDA as the company prepares to file Viaskin Peanut for approval.
Reviewed by:
Purvi Parikh, MD, FACAAI is an adult and pediatric allergist and immunologist at Allergy and Asthma Associates of Murray Hill in New York City. She is on faculty as Clinical Assistant Professor in both departments of Medicine and Pediatrics at New York University School of Medicine.
